An interventional study of Supra-iliac anterior quadratus lumborum block and Pericapsular nerve group block in Supra-Iliac Anterior Quadratus Lumborum Block, Pericapsular Nerve Group Block and Analgesia, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-23.
Sponsored by Tanta University · Not applicable, Interventional, and Treatment
This study aims to compare the analgesic efficacy of supra-iliac anterior quadratus lumborum block (SA-QLB) and pericapsular nerve group (PENG) block in patients undergoing total hip arthroplasty (THA).
Total hip arthroplasty (THA) is one of the most common elective orthopedic procedures, performed to restore mobility, alleviate pain and improve quality of life in patients with degenerative hip joint disease. Its rate is projected to further increase with aging of the population worldwide.
Pericapsular nerve group (PENG) block is a fascial block targets periarticular sensory branches derived from the femoral, obturator and accessory obturator nerves innervating the anterior hip capsule.
The ultrasound-guided quadratus lumborum block (QLB) is a regional anesthetic technique with many described approaches: the lateral QL (QL1) block, the posterior QL (QL2) block, and the anterior QL (transmuscular) block.
1,190 studies on the registry are indexed under Agnosia; 507 are open to participants now.
This study's planned enrollment of 50 is below the median of 77 across 1,023 interventional studies indexed under Agnosia.
Browse Agnosia studies →Tanta University is the lead sponsor of 963 studies on the registry; 304 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients will receive a supra-iliac anterior quadratus lumborum block (SA-QLB) using 20mL of bupivacaine 0.25%.
Other: Supra-iliac anterior quadratus lumborum block
Patients will receive an ultrasound-guided pericapsular nerve group (PENG) block using 20mL of bupivacaine 0.25%.
Other: Pericapsular nerve group block
Patients will receive a supra-iliac anterior quadratus lumborum block (SA-QLB) using 20mL of bupivacaine 0.25%.
Patients will receive an ultrasound-guided pericapsular nerve group (PENG) block using 20mL of bupivacaine 0.25%.
Degree of pain
Each patient will be instructed about postoperative pain assessment with visual analog scale (VAS). VAS (0 represents "no pain" while 10 represents "the worst pain imaginable")
Time frame: 12 hours postoperatively
Total morphine consumption
Rescue analgesia of morphine will be given as 3 mg bolus if the VAS \> 3 to be repeated after 30 min if pain persists until the visual analog scale (VAS) \< 4. VAS will be assessed at post-anesthesia care unit (PACU), 2, 4, 6, 12, 24, and 48 h postoperatively.
Time frame: 48 hours postoperatively
Time to the first rescue analgesia
Time to the first request for the rescue analgesia will be recorded from the end of block to first dose of morphine administrated.
Time frame: 48 hours postoperatively
Time to ambulation
Time to ambulation will be recorded from the end of surgery to the first successful mobilization of the patient, defined as the ability to stand and walk at least 3-5 steps with or without assistance.
Time frame: Till the first successful mobilization (Up to 4 hours)
Length of hospital stay
Length of hospital stay will be recorded from admission till the discharge from hospital.
Time frame: Till discharge from the hospital (Up to 2 weeks)
Incidence of adverse events
Incidence of adverse events such as bradycardia, hypotension, nausea, vomiting, respiratory depression, or any other complication will be recorded.
Time frame: 24 hours postoperatively
Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Supporting information: Study protocol
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tanta University